NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa
The National Institute of Allergy and Infectious Diseases (NIAID) is set to initiate a new research study, HVTN 702, of a new HIV vaccine in South Africa.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: African Health | Allergy | Allergy & Immunology | Infectious Diseases | Pharmaceuticals | Study | Vaccines